She was overwhelmed, but she felt the trial was her best chance for a successful outcome.
Similar Posts
How to Participate in Emerging Technology Program (ETP)
CDER’s Office of Pharmaceutical Quality created the Emerging Technology Program to promote the adoption of innovative approaches to pharmaceutical product design and manufacturing.Disseminated Coccidioidomycosis: Developing Drugs for Treatment
Disseminated Coccidioidomycosis: Developing Drugs for TreatmentPain and Arthritis Products Containing Hidden Ingredients
Learn about the warnings for pain and arthritis products that contain hidden drugs and other hidden ingredients.Summary Metrics of Drug Development Tool Qualification Projects Submitted to FDA
This Table provides the current number of active CDER Drug Development Tool (DDT) Qualification projects overall and by Program (DDT- Animal Model Qualification Program, DDT- Biomarker Qualification Program, DDT- Clinical Outcomes Assessment [COA] Qualification Program). Numbers are also provided byFDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes
The U.S. Food and Drug Administration (FDA) is warning that cases of a rare but serious infection of the genitals and area around the genitals have been reported with the class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors.Sun Pharmaceuticals Medicare Ltd. 9/19/2025
Record Date: 9/19/2025
Entity Name: Sun Pharmaceuticals Medicare Ltd.
FEI Number: 3002957541
Record Type: 483
Country: India
Establishment Type: Sterile Drug Manufacturer